MX2023001461A - Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias. - Google Patents
Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias.Info
- Publication number
- MX2023001461A MX2023001461A MX2023001461A MX2023001461A MX2023001461A MX 2023001461 A MX2023001461 A MX 2023001461A MX 2023001461 A MX2023001461 A MX 2023001461A MX 2023001461 A MX2023001461 A MX 2023001461A MX 2023001461 A MX2023001461 A MX 2023001461A
- Authority
- MX
- Mexico
- Prior art keywords
- delivery
- payload molecules
- compositions
- airway epithelium
- payload
- Prior art date
Links
- 210000000981 epithelium Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000005058 airway cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción proporciona LNP que comprenden moléculas de carga activa, por ejemplo, terapias de ARNm, para el tratamiento de enfermedades o trastornos, que se beneficiarían de la administración de moléculas de carga activa a las células de las vías respiratorias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063062367P | 2020-08-06 | 2020-08-06 | |
PCT/US2021/045038 WO2022032154A2 (en) | 2020-08-06 | 2021-08-06 | Compositions for the delivery of payload molecules to airway epithelium |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001461A true MX2023001461A (es) | 2023-04-26 |
Family
ID=77543659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023001461A MX2023001461A (es) | 2020-08-06 | 2021-08-06 | Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230285310A1 (es) |
EP (1) | EP4192433A2 (es) |
JP (1) | JP2023538260A (es) |
KR (1) | KR20230087443A (es) |
CN (1) | CN116348147A (es) |
AU (1) | AU2021320426A1 (es) |
BR (1) | BR112023001955A2 (es) |
CA (1) | CA3189854A1 (es) |
IL (1) | IL300111A (es) |
MX (1) | MX2023001461A (es) |
TW (1) | TW202214215A (es) |
WO (1) | WO2022032154A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
MA49922A (fr) | 2017-08-18 | 2021-06-02 | Modernatx Inc | Procédés pour analyse par clhp |
FI3864163T3 (fi) | 2018-10-09 | 2024-05-03 | Univ British Columbia | Koostumukset ja järjestelmät, joihin sisältyvät transfektiokompetentit vesikkelit, joissa ei ole orgaanisia liuottimia eikä pesuaineita, sekä niihin liittyvät menetelmät |
WO2023076605A1 (en) * | 2021-10-29 | 2023-05-04 | Modernatx, Inc. | Lipid amines |
TW202332467A (zh) * | 2021-10-29 | 2023-08-16 | 美商現代公司 | 脂質胺 |
WO2023086465A1 (en) * | 2021-11-12 | 2023-05-19 | Modernatx, Inc. | Compositions for the delivery of payload molecules to airway epithelium |
TW202345863A (zh) | 2022-02-09 | 2023-12-01 | 美商現代公司 | 黏膜投與方法及調配物 |
WO2023158486A2 (en) * | 2022-02-15 | 2023-08-24 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
WO2023173203A1 (en) * | 2022-03-14 | 2023-09-21 | Nanovation Therapeutics Inc. | Synthetic method for producing ionizable amino lipids |
CN117396538A (zh) * | 2022-04-12 | 2024-01-12 | 厦门赛诺邦格生物科技股份有限公司 | 一种含有叔胺的非线性聚乙二醇化脂质及其应用 |
WO2024035710A2 (en) * | 2022-08-08 | 2024-02-15 | Advanced Rna Vaccine (Arv) Technologies, Inc. | Sterol based ionizable lipids and lipid nanoparticles comprising the same |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
WO2024095179A1 (en) | 2022-11-04 | 2024-05-10 | Pfizer Inc. | Lipid compounds and uses thereof |
CN117919200A (zh) * | 2024-01-19 | 2024-04-26 | 晟迪生物医药(苏州)有限公司 | 含有可电离脂质的肺部递送系统、其制备方法和应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5840710A (en) * | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
CA2597724A1 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
JP2010519203A (ja) | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
US20100297242A1 (en) * | 2007-10-17 | 2010-11-25 | Tae-Gwan Park | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
EP2326331A4 (en) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION |
WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
ES2579936T3 (es) | 2009-08-20 | 2016-08-17 | Sirna Therapeutics, Inc. | Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico |
EP2485770A4 (en) | 2009-10-08 | 2013-04-10 | Merck Sharp & Dohme | NEW CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR ADMINISTRATION OF OLIGONUCLEOTIDES |
NZ700688A (en) | 2009-12-01 | 2016-02-26 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
US9254327B2 (en) | 2010-05-10 | 2016-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
EP2575767B1 (en) | 2010-06-04 | 2017-01-04 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
ES2888231T3 (es) | 2010-09-20 | 2022-01-03 | Sirna Therapeutics Inc | Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
JP2013545723A (ja) | 2010-09-30 | 2013-12-26 | メルク・シャープ・エンド・ドーム・コーポレイション | オリゴヌクレオチドの送達のための低分子量カチオン性脂質 |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
JP2013545727A (ja) | 2010-10-21 | 2013-12-26 | メルク・シャープ・アンド・ドーム・コーポレーション | オリゴヌクレオチド送達用の新規低分子量カチオン性脂質 |
DK2635265T3 (en) | 2010-11-05 | 2018-07-16 | Sirna Therapeutics Inc | New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery |
EP2663548B1 (en) | 2011-01-11 | 2017-04-05 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
AU2012267578B2 (en) | 2011-06-08 | 2017-04-20 | Translate Bio, Inc. | Cleavable lipids |
US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
ES2921724T1 (es) | 2011-12-07 | 2022-08-31 | Alnylam Pharmaceuticals Inc | Lípidos biodegradables para la administración de agentes activos |
WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
HUE041494T2 (hu) | 2012-02-24 | 2019-05-28 | Arbutus Biopharma Corp | Trialkil-kationos lipidek és alkalmazási módszereik |
KR20140048404A (ko) * | 2012-10-11 | 2014-04-24 | 포항공과대학교 산학협력단 | 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물 |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EP2971013B1 (en) | 2013-03-15 | 2020-08-19 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
AU2016343803B2 (en) | 2015-10-28 | 2021-04-29 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US11969506B2 (en) * | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
WO2019094405A1 (en) * | 2017-11-10 | 2019-05-16 | Board Of Regents, The University Of Texas System | Lipid-based nanoparticles for encapsulation and sustained release of therapeutic agents |
WO2020160397A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
-
2021
- 2021-08-06 EP EP21762908.8A patent/EP4192433A2/en active Pending
- 2021-08-06 KR KR1020237007762A patent/KR20230087443A/ko unknown
- 2021-08-06 US US18/040,485 patent/US20230285310A1/en active Pending
- 2021-08-06 AU AU2021320426A patent/AU2021320426A1/en active Pending
- 2021-08-06 WO PCT/US2021/045038 patent/WO2022032154A2/en active Application Filing
- 2021-08-06 JP JP2023507600A patent/JP2023538260A/ja active Pending
- 2021-08-06 CA CA3189854A patent/CA3189854A1/en active Pending
- 2021-08-06 BR BR112023001955A patent/BR112023001955A2/pt unknown
- 2021-08-06 IL IL300111A patent/IL300111A/en unknown
- 2021-08-06 MX MX2023001461A patent/MX2023001461A/es unknown
- 2021-08-06 CN CN202180068470.XA patent/CN116348147A/zh active Pending
- 2021-08-06 TW TW110129202A patent/TW202214215A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20230285310A1 (en) | 2023-09-14 |
KR20230087443A (ko) | 2023-06-16 |
EP4192433A2 (en) | 2023-06-14 |
BR112023001955A2 (pt) | 2023-04-11 |
CN116348147A (zh) | 2023-06-27 |
TW202214215A (zh) | 2022-04-16 |
CA3189854A1 (en) | 2022-02-10 |
IL300111A (en) | 2023-03-01 |
WO2022032154A3 (en) | 2022-04-21 |
JP2023538260A (ja) | 2023-09-07 |
WO2022032154A2 (en) | 2022-02-10 |
AU2021320426A1 (en) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001461A (es) | Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias. | |
MX2020008581A (es) | Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos. | |
PH12020500309A1 (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
PH12017550069A1 (en) | Tau antisense oligomers and uses thereof | |
ZA202108348B (en) | Angiotensinogen (agt) irna compositions and methods of use thereof | |
PH12020550195A1 (en) | Use of p38 inhibitors to reduce expression of dux4 | |
SG179410A1 (en) | Therapeutic uses of inhibitors of rtp801 | |
MX353461B (es) | PROCESOS PARA PREPARAR COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA ATAXIA TELANGIECTASIA MUTADA Y Rad3 RELACIONADOS (ATR). | |
MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
SG10201808063PA (en) | Compositions for modulating ataxin 2 expression | |
WO2010040023A3 (en) | Methods and compositions for protein delivery | |
PH12020500570A1 (en) | Alpha-synuclein antisense oligonucleotides and uses thereof | |
MX2023001450A (es) | Composiciones y metodos para la inhibicion de la expresion de plp1. | |
MX336711B (es) | Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos. | |
MX2010001608A (es) | Suministro mediado por aav auto-complementario de moléculas de arn interferente para tratar o evitar trastornos oculares. | |
MX2020007439A (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos. | |
MX2022000183A (es) | Lipidos cationicos y usos de estos. | |
MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
MX2021013602A (es) | Inhibidores de jak. | |
MX2020007433A (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos. | |
MX2023000511A (es) | Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones. | |
MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
AU2017248848A1 (en) | Enhanced gene delivery methods | |
MX2021004860A (es) | Piridazinas novedosas. |